UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Revvity Inc. (NYSE:RVTY – Free Report) by 4.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 497,157 shares of the company’s stock after purchasing an additional 20,588 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.45% of Revvity worth $55,314,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also made changes to their positions in the company. New Mexico Educational Retirement Board raised its holdings in shares of Revvity by 3.7% during the second quarter. New Mexico Educational Retirement Board now owns 5,616 shares of the company’s stock worth $625,000 after purchasing an additional 200 shares during the period. Mufg Securities Americas Inc. raised its holdings in shares of Revvity by 7.1% during the second quarter. Mufg Securities Americas Inc. now owns 3,360 shares of the company’s stock valued at $374,000 after buying an additional 223 shares during the last quarter. Hsbc Holdings PLC raised its stake in Revvity by 25.5% during the 2nd quarter. Hsbc Holdings PLC now owns 177,678 shares of the company’s stock valued at $19,762,000 after acquiring an additional 36,050 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Revvity by 10,653.8% in the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock worth $96,304,000 after purchasing an additional 857,526 shares during the period. Finally, Rakuten Investment Management Inc. acquired a new stake in shares of Revvity in the 2nd quarter worth approximately $1,315,000. 86.65% of the stock is owned by institutional investors and hedge funds.
Revvity Price Performance
Shares of Revvity stock opened at $130.98 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The firm’s 50-day simple moving average is $115.72 and its 200-day simple moving average is $101.80. The firm has a market cap of $14.62 billion, a P/E ratio of 62.37, a price-to-earnings-growth ratio of 2.30 and a beta of 1.09. Revvity Inc. has a twelve month low of $81.22 and a twelve month high of $131.75.
Revvity Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio is currently 13.33%.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. Barclays upped their price objective on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Sanford C. Bernstein initiated coverage on shares of Revvity in a research note on Friday, June 26th. They issued a “market perform” rating and a $115.00 price objective for the company. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Robert W. Baird set a $117.00 price target on Revvity in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat, Revvity currently has an average rating of “Hold” and a consensus target price of $110.58.
Read Our Latest Stock Report on RVTY
Revvity Profile
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Recommended Stories
- Five stocks we like better than Revvity
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
